These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 23255781)

  • 21. Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma.
    Fung SY; Lam JW; Chan KC
    Chin Clin Oncol; 2016 Apr; 5(2):18. PubMed ID: 27121878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complementary determination of Epstein-Barr virus DNA load and serum markers for nasopharyngeal carcinoma screening and early detection in individuals at risk in Tunisia.
    Baizig NM; Morand P; Seigneurin JM; Boussen H; Fourati A; Gritli S; Oueslati Z; Touati S; Gamoudi A; Ben Abdallah M; El May M; El May A
    Eur Arch Otorhinolaryngol; 2012 Mar; 269(3):1005-11. PubMed ID: 21805179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epstein-Barr virus serology in early detection and screening of nasopharyngeal carcinoma.
    Ng MH; Chan KH; Ng SP; Zong YS
    Ai Zheng; 2006 Feb; 25(2):250-6. PubMed ID: 16480597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin.
    Ramayanti O; Juwana H; Verkuijlen SA; Adham M; Pegtel MD; Greijer AE; Middeldorp JM
    Int J Cancer; 2017 Jan; 140(1):149-162. PubMed ID: 27600027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of methylation status of Epstein-Barr virus DNA C promoter in the diagnosis of nasopharyngeal carcinoma.
    Zheng XH; Wang RZ; Li XZ; Zhou T; Zhang JB; Zhang PF; Lu LX; Jia WH
    Cancer Sci; 2020 Feb; 111(2):592-600. PubMed ID: 31834989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Seroreactivity against Epstein-Barr virus (EBV) among first-degree relatives of sporadic EBV-associated nasopharyngeal carcinoma in Indonesia.
    Hutajulu SH; Ng N; Jati BR; Fachiroh J; Herdini C; Hariwiyanto B; Haryana SM; Middeldorp JM
    J Med Virol; 2012 May; 84(5):768-76. PubMed ID: 22431025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IgA antibodies against the Epstein-Barr nuclear antigen1 as a valuable biomarker for the diagnosis of nasopharyngeal carcinoma in Tunisian patients.
    Ayadi W; Karray-Hakim H; Feki L; Khabir A; Boudawara T; Ghorbel A; Daoud J; Frikha M; Hammami A
    J Med Virol; 2009 Aug; 81(8):1412-21. PubMed ID: 19551836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
    Guo J; Cui Z; Zheng Y; Li X; Chen Y
    Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polymyositis/dermatomyositis and nasopharyngeal carcinoma: the Epstein-Barr virus connection?
    Chen DY; Chen YM; Lan JL; Chen HH; Hsieh CW; Wey SJ; Lu JJ
    J Clin Virol; 2010 Dec; 49(4):290-5. PubMed ID: 20934910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody against the Epstein-Barr virus BHRF1 protein, a homologue of Bcl-2, in patients with nasopharyngeal carcinoma.
    Liu MY; Shih YY; Chou SP; Chen CJ; Sheen TS; Yang CS; Chen JY
    J Med Virol; 1998 Nov; 56(3):179-85. PubMed ID: 9783682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic value of the Epstein-Barr virus serological markers in patients with nasopharyngeal carcinoma in cases of undetectable primary tumor location.
    Gurtsevitch VE; Senyuta NB; Lomaya MV; Ignatova AV; Dushenkina TE; Repkina IA; Pavlovskaya AI; Mudunov AM
    Vopr Virusol; 2016; 61(5):205-12. PubMed ID: 29323852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of EBV antibody EA-IgA, Rta-IgG and VCA-IgA and SA in serum and the implication of combined assay in nasopharyngeal carcinoma diagnosis.
    Xia C; Zhu K; Zheng G
    Int J Clin Exp Pathol; 2015; 8(12):16104-10. PubMed ID: 26884888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of Stage I nasopharyngeal carcinoma by serologic screening and clinical examination.
    Ji MF; Yu YL; Cheng WM; Zong YS; Ng PS; Chua DT; Ng MH
    Chin J Cancer; 2011 Feb; 30(2):120-3. PubMed ID: 21272444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of specific Epstein-Barr virus IgA and elevated IgG antibodies to viral capsid antigens in nasopharyngeal carcinoma patients.
    Hadar T; Rahima M; Kahan E; Sidi J; Rakowsky E; Sarov B; Sarov I
    J Med Virol; 1986 Dec; 20(4):329-39. PubMed ID: 3025351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
    Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
    mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epstein-Barr virus biomarkers for nasopharyngeal carcinoma in non-endemic regions.
    Gurtsevitch VE; Senyuta NB; Ignatova AV; Lomaya MV; Kondratova VN; Pavlovskaya AI; Dushenkina TE; Maximovich DM; Smirnova KV; Mudunov AM; Lichtenstein AV
    J Gen Virol; 2017 Aug; 98(8):2118-2127. PubMed ID: 28786806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Evaluation of IgG and IgA type antibodies to capsid and early antigens of the Epstein-Barr virus in the diagnosis of nasopharyngeal carcinoma].
    Mendoza J; Rojas A; de la Rosa M; Amador JM; Expósito J; Esquivias J
    Med Clin (Barc); 1991 Nov; 97(16):609-11. PubMed ID: 1662737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis of nasopharyngeal carcinoma by means of recombinant Epstein-Barr virus proteins.
    Littler E; Baylis SA; Zeng Y; Conway MJ; Mackett M; Arrand JR
    Lancet; 1991 Mar; 337(8743):685-9. PubMed ID: 1672175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epstein-Barr virus glycoprotein gH/gL antibodies complement IgA-viral capsid antigen for diagnosis of nasopharyngeal carcinoma.
    Li RC; Du Y; Zeng QY; Tang LQ; Zhang H; Li Y; Liu WL; Zhong Q; Zeng MS; Huang XM
    Oncotarget; 2016 Mar; 7(13):16372-83. PubMed ID: 27093005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.